Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03298451
Recruitment Status : Active, not recruiting
First Posted : October 2, 2017
Last Update Posted : November 1, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 31, 2020
Estimated Study Completion Date : October 30, 2020